Literature DB >> 21466282

Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.

Marly I Roche1, Zhaohua Lu, Julia H Hui, Jacqueline Sharon.   

Abstract

The lipopolysaccharide (LPS) of Francisella tularensis (Ft), the Gram negative bacterium that causes tularemia, has been shown to be a main protective antigen in mice and humans; we have previously demonstrated that murine anti-Ft LPS IgG2a monoclonal antibodies (MAbs) can protect mice against otherwise lethal intranasal infection with the Ft live vaccine strain (LVS). Here we show that four IgG2a anti-LPS MAbs are specific for the O-polysaccharide (O-antigen [OAg]) of Ft LPS. But whereas three of the MAbs bind to immunodominant repeating internal epitopes, one binds to a unique terminal epitope of Ft OAg. This was deduced from its even binding to both long and short chains of the LPS ladder in Western blots, its rapid decrease in ELISA binding to decreasing solid-phase LPS concentrations, its inability to compete for LPS binding with a representative of the other three MAbs, and its inability to immunoprecipitate OAg despite its superior agglutination titer. Biacore analysis showed the end-binding MAb to have higher bivalent avidity for Ft OAg than the internal-binding MAbs and provided an immunogenicity explanation for the predominance of internal-binding anti-Ft OAg MAbs. These findings demonstrate that non-overlapping epitopes can be targeted by antibodies to Ft OAg, which may inform the design of vaccines and immunotherapies against tularemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466282      PMCID: PMC3119334          DOI: 10.1089/hyb.2010.0083

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  54 in total

1.  Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity.

Authors:  S Villeneuve; H Souchon; M M Riottot; J C Mazie; P Lei; C P Glaudemans; P Kovác; J M Fournier; P M Alzari
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 2.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain.

Authors:  K L Elkins; C M Bosio; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.

Authors:  Shite Sebastian; Simon T Dillon; Jillian G Lynch; LeeAnn T Blalock; Emmy Balon; Kristin T Lee; Laurie E Comstock; J Wayne Conlan; Eric J Rubin; Arthur O Tzianabos; Dennis L Kasper
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

Review 5.  Francisella tularensis vaccines.

Authors:  Kate F Griffin; Petra C F Oyston; Richard W Titball
Journal:  FEMS Immunol Med Microbiol       Date:  2007-02-22

6.  Preparation of monoclonal antibodies for detection and identification of Francisella tularensis.

Authors:  Akitoyo Hotta; Akihiko Uda; Osamu Fujita; Kiyoshi Tanabayashi; Akio Yamada
Journal:  Clin Vaccine Immunol       Date:  2006-11-22

7.  Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis.

Authors:  Girish S Kirimanjeswara; Jacqueline M Golden; Chandra Shekhar Bakshi; Dennis W Metzger
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Production and characterization of a monoclonal antibody to Francisella tularensis lipopolysaccharide.

Authors:  Michael J Gubbins; Jody D Berry; Lisa Schmidt; Teresa Cabral; Amin Kabani; Raymond S Tsang
Journal:  Hybridoma (Larchmt)       Date:  2007-04

9.  Immunodominant Francisella tularensis antigens identified using proteome microarray.

Authors:  Jim E Eyles; Berkay Unal; Margaret Gill Hartley; Sarah L Newstead; Helen Flick-Smith; Joann L Prior; Petra C F Oyston; Arlo Randall; Yunxiang Mu; Siddiqua Hirst; Douglas M Molina; D Huw Davies; Tim Milne; Kate F Griffin; Pierre Baldi; Rick W Titball; Philip L Felgner
Journal:  Proteomics       Date:  2007-06       Impact factor: 3.984

10.  [The determination of the antigenic determinant of protective monoclonal antibodies specific to the Francisella tularensis lipopolysaccharide].

Authors:  V S Khlebnikov; I R Golovlev; N V Tokhtamysheva; S F Averin; D P Kulevatskiĭ; G K Grechko; A A Averina; S S Vetchinin
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1993 Jan-Feb
View more
  18 in total

Review 1.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Authors:  Michael J Rynkiewicz; Zhaohua Lu; Julia H Hui; Jacqueline Sharon; Barbara A Seaton
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

3.  Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Authors:  Zhaohua Lu; Hillary M Perkins; Jacqueline Sharon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

4.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

5.  Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Authors:  Zhaohua Lu; Guillermo Madico; Marly I Roche; Qi Wang; Julia H Hui; Hillary M Perkins; Joseph Zaia; Catherine E Costello; Jacqueline Sharon
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

6.  A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.

Authors:  Qi Wang; Xiaofeng Shi; Nancy Leymarie; Guillermo Madico; Jacqueline Sharon; Catherine E Costello; Joseph Zaia
Journal:  Biochemistry       Date:  2011-11-28       Impact factor: 3.162

7.  Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

8.  Metabolic labeling to characterize the overall composition of Francisella lipid A and LPS grown in broth and in human phagocytes.

Authors:  Jason H Barker; Justin W Kaufman; De-Sheng Zhang; Jerrold P Weiss
Journal:  Innate Immun       Date:  2013-05-31       Impact factor: 2.680

9.  The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Qi Wang; Catherine E Costello; Joseph Zaia; Barbara A Seaton; Jacqueline Sharon
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

10.  B-cell epitopes in GroEL of Francisella tularensis.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Guillermo Madico; Sheng Li; Chiou-Ying Yang; Hillary M Perkins; Seshi R Sompuram; Vani Kodela; Tong Liu; Timothy Morris; Daphne Wang; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.